Kinder Morgan Inc vs Revvity Inc — how do they compare? Kinder Morgan Inc trades at $32.49 (market cap $71.81B), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: Kinder Morgan Inc is far larger — about 4.2× Revvity Inc's market cap, and Kinder Morgan Inc pays the higher dividend (3.66%). Which is the better fit depends on your goals — on Pluang, investors hold Kinder Morgan Inc for 150 Days and Revvity Inc for 12 Days on average.
| KMI | RVTY | |
|---|---|---|
Market Cap | $71.81B | $16.98B |
Volume | 16,921,908 | 1,456,900 |
Sector | Energy | Health |
52-Week High | $34.31 | $157.36 |
52-Week Low | $25.84 | $82.26 |
Typical Hold Time | 150 Days | 12 Days |
Enterprise Value | $103.86B | $19.30B |
Dividend Yield | 3.66% | 0.18% |
Signals from Pluang's Aura AI — not financial advice
Kinder Morgan (KMI) trades at $32.25, up 1.35% with a bullish technical signal and strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters, posting 18% net income margin growth in 2025. Analyst consensus shows mixed sentiment with 47% buy ratings and a $37.20 price target, representing 15% upside potential. Recent news highlights the company's $6-7B growth runway from Southeast gas demand and data center expansion.
KMI offers investors stable fee-based revenue from energy infrastructure with a compelling dividend yield. The stock presents growth potential from natural gas demand trends but faces risks from energy market volatility and high debt levels. Current valuation metrics appear reasonable given the company's profitability and growth backlog, though technical indicators show some overbought conditions near-term.
RVTY trades at $152.16, down 0.94% today, near its recent 52-week high of $158.28 (Defense World, 2026-10-01). The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for three consecutive quarters. Recent positive developments include a Zacks upgrade to Buy (2026-10-02) and the launch of a new Type 1 diabetes screening kit in Europe (Business Wire, 2026-09-24).
The outlook is positive, supported by earnings momentum and strategic expansions, but the stock's premium valuation (P/E of 73.15) and margin pressures pose risks. Analyst consensus is bullish with a $132.13 price target, though the current price exceeds it, suggesting near-term consolidation may occur before further gains.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 83,000 miles in pipelines and over 140 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
Read more on KMI →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →